A single vaccine from Moderna can protect against SARS-CoV-2 and influenza more effectively than separate vaccines.
Moderna's mRNA-based vaccine for both SARS-CoV-2 and influenza is proven more effective in adults over 50 years old.
Combination vaccines utilizing mRNA technology show promise for public health despite challenges in development costs and time.